PROPHET
Pulmonary Arterial Hypertension
Key Facts
About Occlutech
Occlutech is a well-established, privately-held medical device company with a global commercial footprint, having implanted over 220,000 of its occluder devices in over 70 countries. Its core business is built on a proven portfolio of minimally invasive implants for structural heart interventions, including devices for patent foramen ovale (PFO), atrial septal defects (ASD), and patent ductus arteriosus (PDA). The company is now advancing its growth strategy through clinical development of a novel Atrial Flow Regulator (AFR) device for heart failure and pulmonary hypertension, positioning it in large, high-need therapeutic markets.
View full company profileAbout OncoHost
AI‑driven plasma proteomics platform that predicts immunotherapy response for oncology patients.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Tadliq® (Tadalafil Oral Suspension) | CMP Pharma | Approved |
| JTV-161 | Akros Pharma | Phase1 |
| Soft Mist Inhaler for PAH (with unnamed Pharma Partner) | Resyca | Not Disclosed |
| LTSE-2578 | Structure Therapeutics | Phase 1 |
| Tyvaso DPI® | MannKind Corp | Approved |
| F230 | Gyre Therapeutics | Not Specified |